Cargando…

Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania

Long acting injectable antipsychotics (LAIs) are considered the ideal treatment for schizophrenia, especially for young patients with high rates of non-adherence. In the current COVID-19 pandemic, it has been reported that the administration of LAIs decreased in some areas. The aim of this study was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miron, Ana A., Ifteni, Petru I., Teodorescu, Andreea, Petric, Paula S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316377/ https://www.ncbi.nlm.nih.gov/pubmed/35885792 http://dx.doi.org/10.3390/healthcare10071265

Ejemplares similares

Rating Opportunity for Long-Acting Injectable Antipsychotic Initiation Index (ROLIN)
por: Ifteni, Petru, et al.
Publicado: (2021)

Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics—An Observational Study
por: Miron, Ana Aliana, et al.
Publicado: (2023)

Long-acting injectable antipsychotics treatment during COVID-19 pandemic – A new challenge
por: Ifteni, Petru, et al.
Publicado: (2020)

Switch from Olanzapine Long-Acting Injectable to its Oral Equivalent during COVID-19 Pandemic: a Real World Observational Study
por: Miron, Ana-Aliana, et al.
Publicado: (2022)

Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia
por: Potkin, Steven, et al.
Publicado: (2013)

Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment
por: Moga, Silvia, et al.
Publicado: (2021)

Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study
por: McKee, Kyle A., et al.
Publicado: (2021)

The Effect of Switching to Long-Acting Injection (LAI) Antipsychotic Therapy on Patients with Schizophrenia
por: STRUNOIU, LIVIA MIHAELA, et al.
Publicado: (2021)

Schizophrenia long-acting antipsychotics initiation index (SLAAII)
por: Ifteni, P., et al.
Publicado: (2021)

Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection
por: Moga, Silvia, et al.
Publicado: (2022)

Comparison of hospitalizations in patients on first generation versus second generation long acting injectable (LAI) antipsychotics
por: Rasool, Seemab, et al.
Publicado: (2021)

An 8-year longitudinal study of long-acting injectable (LAI) antipsychotics. Prescription trends and therapeutic drug monitoring to inform precision dosing
por: Piacentino, D., et al.
Publicado: (2022)

The Use of Long-Acting Injectable Antipsychotics (LAI) in the Serious Mental Illness (SMI) Patients Enrolled in an Assertive Community Treatment (ACT) Program
por: Yee, Maria Ruiza, et al.
Publicado: (2021)

Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic
por: Haider, Batool, et al.
Publicado: (2023)

F228. EFFECTIVENESS OF PALIPERIDONE PALMITATE VS OTHER LONG-ACTING INJECTABLE (LAI) ANTIPSYCHOTICS – AN ELECTRONIC CASE REGISTER STUDY
por: Patel, Rashmi, et al.
Publicado: (2018)

Psychiatric Nurses’ Knowledge and Practice Barriers to Administering Long-Acting Injectable (LAI) Antipsychotics in Taiwan: A Mixed-Methods Study
por: Lin, Yao-Yu, et al.
Publicado: (2023)

The place of Long Acting Injectables (LAI) in the treatment of Schizophrenia: Current perspectives
Publicado: (2022)

Switching bipolar disorder patients treated with clozapine to another antipsychotic medication: a mirror image study
por: Ifteni, Petru, et al.
Publicado: (2017)

Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics
por: Mace, Shubhra, et al.
Publicado: (2019)

Prescribing patterns of long-acting injectable antipsychotics in a community setting in South Africa
por: Veyej, Nabila, et al.
Publicado: (2022)

Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey
por: Zhdanava, Maryia, et al.
Publicado: (2022)

A study on blood pressure changes following Olanzapine Long Acting Injection (LAI) in schizophrenia
por: Gakkhar, Shivam, et al.
Publicado: (2022)

Efficacy and safety of second-generation antipsychotic long-acting injections (SGA LAIs) in maintenance treatment of bipolar disorder: protocol for a systematic review and meta-analysis
por: Prajapati, Asta R, et al.
Publicado: (2016)

WHODAS Assessment Feasibility and Mental Health Impact on Functional Disability in Systemic Lupus Erythematosus
por: Duca, Liliana, et al.
Publicado: (2022)

T213. TREND OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS USE IN ASIA: FINDINGS FROM REAP ANTIPSYCHOTIC STUDIES
por: Lin, Shih-Ku, et al.
Publicado: (2020)

Clozapine Efficacy in a Case of Severe Treatment-Resistant Postpartum Psychosis
por: Teodorescu, Andreea, et al.
Publicado: (2021)

Association between Inflammation and Thrombotic Pathway Link with Pathogenesis of Depression and Anxiety in SLE Patients
por: Duca, Liliana, et al.
Publicado: (2023)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

T231. PALIPERIDONE LONG-ACTING INJECTABLE (LAI) IS ASSOCIATED WITH A LOWER INTAKE OF BENZODIAZEPINES AND A LOWER NUMBER OF ADMISSIONS COMPARED WITH OTHER LAIS IN A COHORT OF PATIENTS WITH SCHIZOPHRENIA
por: Garcia-Carmona, Juan-Antonio
Publicado: (2018)

Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of new LAI products
por: Gomeni, Roberto, et al.
Publicado: (2022)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: Lindenmayer, JP
Publicado: (2010)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

Population pharmacokinetics and dosing of long-acting injectable antipsychotics
por: Kim, David D., et al.
Publicado: (2021)

Long-acting injectable antipsychotics during pregnancy: An update
por: Paraschakis, A., et al.
Publicado: (2021)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

PM499. Improvement of cognitive function before and after 2-year treatment with long-acting injection (LAI) of antipsychotics evaluated by NIRS using single word-induced hemoglobin variation as an index
por: Shoji, Yoshihisa, et al.
Publicado: (2016)

Lais /
por: France, Marie de
Publicado: (1994)

Evaluation of adherence in patients prescribed long-acting injectable antipsychotics: A comparison of biweekly versus monthly administered neuroleptics
por: Carr, Chelsea N., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fc47n7bv3r4cpflvt51u4kgkbl